Search

GlaxoSmithKline PLC

Ouvert

SecteurSoins de santé

1,847.5 1.37

Résumé

Variation du prix de l'action

24h

Actuel

Min

1816

Max

1858.5

Chiffres clés

By Trading Economics

Revenu

498M

2.1B

Ventes

561M

8.5B

P/E

Moyenne du Secteur

13.748

90.422

BPA

0.55

Rendement du dividende

3.55

Marge bénéficiaire

25.085

Employés

68,629

EBITDA

129M

3.4B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-0.02% downside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.55%

2.13%

Prochains Résultats

4 févr. 2026

Date du Prochain Dividende

9 avr. 2026

Date du Prochain Détachement de Dividende

19 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.1B

74B

Ouverture précédente

1846.13

Clôture précédente

1847.5

Sentiment de l'Actualité

By Acuity

36%

64%

106 / 352 Classement par Healthcare

GlaxoSmithKline PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 janv. 2026, 11:34 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

RAPT Therapeutics Shares Jump Following Acquisition by GSK

20 janv. 2026, 10:40 UTC

Acquisitions, Fusions, Rachats

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20 janv. 2026, 07:47 UTC

Acquisitions, Fusions, Rachats

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

22 déc. 2025, 11:55 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics Boosts U.S. Presence With $280 Million GSK Facility Deal

20 janv. 2026, 21:45 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 janv. 2026, 14:53 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 janv. 2026, 13:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

GSK's RAPT Deal Helps Address Looming Drug Patent Cliff -- Market Talk

20 janv. 2026, 13:28 UTC

Market Talk
Acquisitions, Fusions, Rachats

GSK's Deal to Buy RAPT Is the Right Risk -- Market Talk

20 janv. 2026, 12:10 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 janv. 2026, 07:15 UTC

Acquisitions, Fusions, Rachats

GSK Expects to Complete RAPT Buy in 1Q

20 janv. 2026, 07:15 UTC

Acquisitions, Fusions, Rachats

GSK: RAPT Buy Subject to Customary Closing Conditions

20 janv. 2026, 07:14 UTC

Acquisitions, Fusions, Rachats

GSK to Launch Tender Offer to Buy RAPT Common Stock Within 10 Business Days

20 janv. 2026, 07:14 UTC

Acquisitions, Fusions, Rachats

GSK: Ozureprubart Rights Exclude Mainland China, Macau, Taiwan, Hong Kong

20 janv. 2026, 07:13 UTC

Acquisitions, Fusions, Rachats

GSK Gets Global Rights to the Ozureprubart Program Under RAPT Deal

20 janv. 2026, 07:13 UTC

Acquisitions, Fusions, Rachats

GSK PLC: Agreement Simplifies ViiV's Shareholder Structure

20 janv. 2026, 07:13 UTC

Acquisitions, Fusions, Rachats

GSK PLC to Get Special Div of $0.250B

20 janv. 2026, 07:08 UTC

Acquisitions, Fusions, Rachats

GSK Estimated Upfront Investment Is $1.9B

20 janv. 2026, 07:08 UTC

Acquisitions, Fusions, Rachats

GSK Offering RAPT Therapeutics Hldrs $58.00 Per Shr

20 janv. 2026, 07:07 UTC

Acquisitions, Fusions, Rachats

GSK PLC to Buy RAPT Therapeutics for $2.2 Billion

20 janv. 2026, 07:06 UTC

Acquisitions, Fusions, Rachats

GSK PLC to Buy RAPT Therapeutics

20 janv. 2026, 00:21 UTC

Acquisitions, Fusions, Rachats

Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1B

16 janv. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

30 déc. 2025, 08:45 UTC

Market Talk
Acquisitions, Fusions, Rachats

A GSK, AstraZeneca Merger Could Be a Possibility -- Market Talk

22 déc. 2025, 11:40 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics Boosts U.S. Presence With $280M GSK Facility Deal

22 déc. 2025, 11:39 UTC

Market Talk

U.S. Pressure Clouds GSK's Outlook -- Market Talk

22 déc. 2025, 00:16 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Plan Additional Investment to Expand Production Capacity

22 déc. 2025, 00:15 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: To Acquire Full Stake in GSK-Owned Human Genome Sciences in Rockville, Md.

22 déc. 2025, 00:15 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics to Buy U.S. Drug Production Facility From GSK for $280M

21 nov. 2025, 12:28 UTC

Market Talk

GSK Unlikely to Face Material Impact from AnaptysBio Litigation -- Market Talk

6 nov. 2025, 16:16 UTC

Résultats

Moderna's Quarter Wasn't As Bad as It Could Have Been. The Stock is Up -- Barrons.com

GlaxoSmithKline PLC prévision

Objectif de Prix

By TipRanks

-0.02% baisse

Prévisions sur 12 Mois

Moyen 1,817.08 GBX  -0.02%

Haut 2,250 GBX

Bas 1,500 GBX

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

15 ratings

3

Achat

8

Maintien

4

Vente

Sentiment

By Acuity

106 / 352Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat